This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q86.0 / Special Copayment Reduction: V157 / Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Dysmorphic features are congenital; neurocognitive and neuropsychiatric/behavioral disorders persist into adulthood |
| 1. History | First described by Jones & Smith in 1973; FASD spectrum concept established |
| 2. Epidemiology | Worldwide FAS birth prevalence about 1.5/1,000; total FASD estimated at 7–10/1,000 |
| 3. Etiology and genetics | Prenatal alcohol exposure; ADH/ALDH polymorphisms; epigenetic mechanisms |
| 4. Pathophysiology | Acetaldehyde toxicity, oxidative stress, neuronal death, CREB and BDNF suppression |
| 5. Clinical features | Facial dysmorphism, growth failure, neurocognitive impairment, ADHD, behavioral problems |
| 6. Diagnostic criteria | 4-Digit Code, NOFAS criteria; IOM/CDC criteria; FASD spectrum classification |
| 7. Differential diagnosis | 22q11.2 deletion syndrome, Williams syndrome, isolated ADHD, prenatal drug exposure |
| 8. Laboratory and imaging findings | Brain MRI, neurocognitive testing, chromosomal analysis, hearing and vision testing |
| 9. Treatment | Multidisciplinary rehabilitation; methylphenidate; behavioral therapy; sensory integration therapy |
| 10. Complications | Secondary disabilities: crime, substance abuse, mental illness, unemployment, etc. |
| 11. Prognosis | Early diagnosis and a stable environment are key to preventing secondary disabilities; reduced quality of life in adulthood |
| 12. Prevention | Complete abstinence from alcohol during pregnancy; SBIRT strategy; prenatal education and counseling |
| 13. References | Jones KL & Smith DW (1973) Recognition of FAS and 9 other papers |
Historical observations of the effects of alcohol during pregnancy on the fetus date back to antiquity. The Book of Judges in the Bible and ancient Greek and Carthaginian texts contain records prohibiting newlyweds from drinking, and in 18th-century England, abnormalities were observed in children born to women who drank during the "Gin Epidemic." However, fetal alcohol syndrome (FAS) was formally defined medically only in 1973, when the American pediatricians Kenneth Lyons Jones and David W. Smith first described, in the Lancet, the pattern of characteristic facial dysmorphism, growth retardation, and central nervous system abnormalities observed in 11 children as "fetal alcohol syndrome."
Earlier, in 1968, the French pediatricians Paul Lemouël and Jürgen Eckel and others had described malformations in children born to alcohol-dependent mothers, but did not explicitly identify alcohol as the direct cause. After Jones and Smith's 1973 paper, FAS began to attract attention as an important cause of preventable congenital anomalies. In 1978, the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics officially recommended complete abstinence from alcohol during pregnancy.
In 1996, the US Institute of Medicine (IOM) proposed the concept of fetal alcohol spectrum disorders (FASD), which includes not only FAS but also alcohol-related neurodevelopmental disorder (ARND) and alcohol-related birth defects (ARBD). This concept was subsequently reflected in the diagnostic guidelines of several countries and organizations, including Canada, Australia, and the WHO. In 2004, the 4-Digit Diagnostic Code was developed, providing a framework for systematically classifying FASD subtypes by separately quantifying the degree of alcohol exposure, facial dysmorphism, growth impairment, and neurodevelopmental impairment. In Korea, it is managed under Special Copayment Reduction code V157, and the need for awareness and diagnostic education continues to be emphasized.
The worldwide birth prevalence of fetal alcohol syndrome (FAS) is estimated at about 1.5/1,000, and that of FASD as a whole is reported as 7–10/1,000 (May et al., 2018). This suggests that FASD is a major cause of congenital neurological disorders, occurring more frequently than intellectual disability and cerebral palsy. There is wide regional variation, with higher FASD prevalence reported in some areas (certain regions of South Africa, parts of the United States, Russia).
The frequency of alcohol consumption during pregnancy differs by country. According to WHO reports, about 10% of pregnant women worldwide drink alcohol during pregnancy, and about 1% of them engage in binge drinking. In Korea, the drinking rate among pregnant women has been declining compared with the past, but drinking is still reported in some pregnant women, and diagnosis is often missed due to lack of awareness.
FAS is one of the most common preventable causes of intellectual disability. The risk is higher in socioeconomically vulnerable groups, alcohol-dependent women, and unplanned pregnancies. Alcohol exposure in early pregnancy (especially the first trimester) has the greatest impact on facial dysmorphism, while alcohol exposure throughout the entire pregnancy is associated with neurodevelopmental abnormalities.
The cause of FAS is alcohol (ethanol) exposure during pregnancy; it is not a genetic disease caused by a specific single-gene mutation. However, maternal polymorphisms in alcohol-metabolizing enzyme genes affect the alcohol concentration to which the fetus is exposed and the degree of toxicity. The rs1229984 (Arg48His) polymorphism of alcohol dehydrogenase (ADH1B) and the rs671 (Lys487Glu) polymorphism of aldehyde dehydrogenase (ALDH2) affect the rate of acetaldehyde accumulation, and these genotypes are associated with susceptibility to FASD. The ALDH2*2 allele, common in East Asians (associated with the alcohol flush reaction), has a drinking-suppressing effect that lowers the drinking rate itself, but acetaldehyde toxicity is more severe when alcohol is consumed.
The fetus has a very limited capacity to break down alcohol compared with adults. The placenta allows alcohol to pass freely, so fetal blood alcohol concentrations remain nearly identical to maternal levels, and even higher concentrations may persist in fetal cerebrospinal fluid. The timing, dose, duration, and frequency of alcohol exposure all affect the severity of FASD. There is no safe amount of alcohol, and any amount of alcohol can be harmful to the fetus.
Epigenetics research has shown that alcohol alters gene expression over the long term through abnormal DNA methylation patterns, histone modifications, and changes in noncoding RNA (miRNA) expression. There is experimental evidence that some of these epigenetic changes may be transmitted to subsequent generations, but the clinical significance of intergenerational transmission in humans is not yet clear.
The toxic mechanisms by which ethanol and its primary metabolite acetaldehyde affect fetal development are multiple. First, oxidative stress: excessive reactive oxygen species (ROS) are generated during ethanol metabolism, causing lipid peroxidation, protein oxidation, and DNA damage. The fetal antioxidant defense system (catalase, SOD, glutathione, etc.) is immature and therefore more vulnerable to oxidative stress.
Second, neuronal death: alcohol inhibits NMDA (N-methyl-D-aspartate) receptors and activates GABA-A receptors, causing excessive neuronal inhibition and promoting programmed cell death (apoptosis) of developing neurons. In particular, alcohol exposure during periods of active synaptic development and neural pruning causes long-term abnormalities in circuit formation.
Third, abnormal cell migration and differentiation: alcohol impairs the function of L1 cell adhesion molecule (L1-CAM), disrupting the radial migration of neurons and causing structural brain abnormalities such as abnormal formation of the corpus callosum, gyral abnormalities, and cerebellar hypoplasia. Abnormal migration of neural crest cells is the pathophysiological basis of the characteristic facial dysmorphism (smooth philtrum, thin upper lip, short palpebral fissures).
Fourth, suppression of neurotrophic and growth factors: alcohol suppresses brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF-1), and nerve growth factor (NGF) signaling, impairing neuronal survival, growth, and synapse formation. Inhibition of CREB (cAMP response element-binding protein) phosphorylation impairs hippocampal long-term potentiation (LTP), forming the basis of impaired memory formation.
Fifth, epigenetic mechanisms: alcohol inhibits the production of SAM (S-adenosylmethionine), the substrate of DNA methyltransferase (DNMT), and alters histone deacetylase (HDAC) activity, causing abnormal expression of development-related genes (Hox, Pax, Oct4, etc.).
The three characteristic facial features of FAS are: ① absent or flattened philtrum (smooth philtrum; flattening of the lip-philtrum ridges); ② thin vermilion border of upper lip; ③ short palpebral fissure length. These three features result developmentally from ethanol-induced abnormal migration of neural crest cells. Additional features include narrowly spaced eyes (hypotelorism), epicanthal folds, nasal abnormalities (short, upturned nose), microtia, and Klinefelter ears. The facial dysmorphism of FAS is most prominent under 3 years of age and in some cases partly softens with growth.
Prenatal and postnatal growth failure is a major feature of FAS. Low birth weight, reduced length, and microcephaly (head circumference <10th percentile) are characteristic, and catch-up growth often does not occur despite adequate nutrition. Microcephaly is closely associated with the neurological prognosis.
Structural abnormalities (agenesis/hypoplasia of the corpus callosum, cerebellar hypoplasia, hippocampal atrophy, basal ganglia abnormalities) may be seen on MRI. Functional abnormalities include reduced intelligence (mean IQ 70–75), ADHD, executive dysfunction, memory and learning impairment, language impairment, and impaired social judgment. Epilepsy occurs in about 10–20%. In the neonatal period, irritability, feeding difficulties, and sleep disturbances may occur.
Congenital heart defects (atrial and ventricular septal defects, patent ductus arteriosus), urinary tract malformations (renal dysplasia, horseshoe kidney), musculoskeletal abnormalities (joint contractures, finger and toe anomalies), visual abnormalities (strabismus, optic nerve hypoplasia), and hearing loss may be present.
The diagnosis of FAS is clinical, and there is no specific biological marker. The main diagnostic systems are the IOM/CDC criteria, the Canadian guidelines (FASD Research Network), and the 4-Digit Diagnostic Code (Astley & Clarren).
CDC/IOM criteria (definite FAS): ① all three facial features (smooth philtrum, thin upper lip, short palpebral fissures) present; ② prenatal or postnatal growth failure (height or weight ≤10th percentile, or microcephaly ≤10th percentile); ③ CNS abnormality (one or more of structural, neurological, or functional); ④ confirmed prenatal alcohol exposure (not required; if the three criteria are met, the diagnosis can be made even without alcohol exposure).
FASD spectrum classification: divided into FAS (complete form), pFAS (partial FAS), ARND (alcohol-related neurodevelopmental disorder; CNS functional abnormality without facial dysmorphism + confirmed alcohol exposure), and ARBD (alcohol-related birth defects). When there is no facial dysmorphism but a history of alcohol exposure and neurodevelopmental impairment are clear, ARND is diagnosed.
Taking a history of prenatal alcohol exposure is important for diagnosis, but because of social stigma, mothers often deny drinking, which can delay diagnosis. In adopted or foster children, the history of alcohol exposure may be unknown, so diagnosis based on clinical findings is needed.
22q11.2 deletion syndrome (DiGeorge/velocardiofacial syndrome): heart defects, cleft palate, and a characteristic facial appearance, but the smooth philtrum and thin upper lip differ. Confirmed by FISH or CMA.
Williams syndrome (7q11.23 deletion): characterized by a sociable personality, "elfin" facies, aortic stenosis, and hypercalcemia. Confirmed by CMA/FISH.
Cornelia de Lange syndrome: characteristic facies (synophrys, brachydactyly), growth retardation, developmental delay. Mutations in genes such as NIPBL.
Prenatal drug exposure (cocaine, methamphetamine, benzodiazepines): growth failure and neurobehavioral disorders are similar, but the pattern of facial dysmorphism differs.
Isolated ADHD: inattention and hyperactivity are similar, but there is no facial dysmorphism, growth failure, or structural brain abnormality. Differentiated by taking a history of alcohol exposure.
Hypothyroidism (congenital): growth failure and reduced intelligence are present, but it can be differentiated by TSH/fT4 testing, and treatment differs.
Brain MRI: agenesis or hypoplasia of the corpus callosum (about 6–7% of FAS), cerebellar hypoplasia, cortical dysplasia, basal ganglia abnormalities, hippocampal atrophy. Quantitative MRI (volumetry) can measure reduced brain volume and be correlated with the neurodevelopmental prognosis. Diffusion tensor imaging (DTI) is also used to assess abnormalities in white matter connectivity.
Head circumference measurement: confirms microcephaly (head circumference ≤10th or ≤3rd percentile).
Neurocognitive testing (in consultation with psychiatry and pediatrics): intelligence testing (K-WISC/K-WAIS), attention testing (ATA, ADHD scales), executive function testing (WCST, BRIEF), memory and language testing, and social cognition assessment. An adaptive behavior scale (Vineland-II) is also essential.
Chromosomal karyotyping and CMA (chromosomal microarray): performed to differentiate other genetic syndromes whose clinical phenotype resembles FAS. Needed when the cause of facial dysmorphism is unclear.
Electrocardiography and echocardiography: to check for associated congenital heart defects.
Hearing and vision testing: to check for hearing loss (both conductive and sensorineural are possible), strabismus, and refractive errors.
Renal ultrasound: to check for associated renal malformations.
Positron emission tomography (PET) and functional MRI (fMRI): used for research purposes to assess functional abnormalities of the frontal lobe, basal ganglia, and cerebellum.
Because FAS/FASD is a lifelong condition with no cure, the goals of treatment are prevention of secondary disabilities and strengthening of adaptive abilities. Integrated management by a multidisciplinary team (pediatrics, neurology, psychiatry, psychologists, speech therapists, occupational therapists, social workers, education specialists) is essential.
Pharmacotherapy: for ADHD symptoms, methylphenidate or amphetamine preparations are used similarly to general ADHD. However, FAS/ADHD may respond less to stimulants than general ADHD, so dose adjustment is needed. Atypical antipsychotics such as risperidone may be used for aggression and impulsivity. Mood stabilizers (valproate, lithium) are considered for mood instability. Standard anticonvulsants are used for epilepsy.
Neurodevelopmental rehabilitation: speech therapy (language delay, communication skills), occupational therapy (sensory integration, fine motor skills), physical therapy (gross motor development, balance), and special education (individualized education program, IEP) are more effective the earlier they begin. Behavior modification therapy (Applied Behavior Analysis, ABA) is useful for reducing problem behaviors.
Home environment and parenting support: a stable and predictable home environment is a protective factor in preventing secondary disabilities. In early adoption or foster placement, linkage with trained caregivers is important. Family education and psychological support programs are recommended. The FAS family resource program developed in Canada (FASD Learning and Advocacy Network, FASD-LAN) is a resource that can also be applied in the Korean setting.
Management in adulthood: adult patients with FAS may experience difficulties with independent living, job adjustment, money management, and legal problems, so ongoing case management and linkage with social services are needed.
Secondary disabilities in patients with FAS/FASD are complications that stem from the original neurological damage but are aggravated by environmental factors. According to research by Streissguth et al., about 90% of adults with FASD have mental health problems (depression, anxiety, psychosis, suicide attempts), about 60% drop out of school, about 50% experience unemployment or unstable employment, and about 60% experience legal problems or incarceration. The risk of drug and alcohol abuse is also markedly higher.
When congenital heart defects are present, there is a risk of heart failure and infective endocarditis, and when renal malformations are present, there is a risk of recurrent urinary tract infections and chronic renal failure.
Epilepsy occurs in about 10–20%, and quality of life is markedly reduced when it progresses to drug-resistant epilepsy. Victimization through exploitation (sexual exploitation, financial exploitation) due to impaired social judgment is also commonly reported in adult patients with FASD.
The neurocognitive damage of FAS/FASD is irreversible and lifelong. However, there are clearly defined protective and risk factors that determine prognosis. Protective factors for preventing secondary disabilities include ① early diagnosis before age 6, ② a stable home environment free of abuse and neglect (even when growing up in a home other than with biological parents, a stable environment is better), ③ qualified caregivers, ④ appropriate special education services, and ⑤ an environment without exposure to violence. When these protective factors are met, the incidence of secondary disabilities (legal problems, mental illness, substance abuse, etc.) is markedly lower.
In general, even with a low IQ, many patients with FAS/FASD can live semi-independently in the community when sufficient support is provided. However, because difficulties persist with complex executive function demands (money management, adherence to social norms), support systems need to be maintained into adulthood. In the absence of physical complications such as congenital heart defects, life expectancy itself may be similar to that of the general population, but the risk of early death from accidents, self-harm, and complications is higher in some.
Fetal alcohol syndrome is a completely preventable disease. If no alcohol is consumed during pregnancy, FAS does not occur. This is why the WHO, the CDC, the Korea Disease Control and Prevention Agency (KDCA), and others recommend complete abstinence from alcohol during pregnancy.
Role of clinicians: educate all women of childbearing age, especially those who may become pregnant, about the fetal toxicity of alcohol and recommend abstinence. Systematic assessment of drinking habits at the first prenatal visit is recommended. The SBIRT (Screening-Brief Intervention-Referral to Treatment) strategy has been shown to be effective in screening pregnant women for drinking early and reducing drinking through brief behavioral counseling. Simple screening tools such as AUDIT-C, TWEAK, and T-ACE are used to screen pregnant women for drinking.
Social and policy prevention: includes warning labels on alcoholic beverage containers advising pregnant women not to drink (implemented in several countries, including Korea), school and community FASD education campaigns, and improved access to treatment for alcohol-dependent women. In particular, because unplanned pregnancy is a major risk factor for alcohol exposure in early pregnancy, abstinence counseling linked with contraceptive education for women of childbearing age is effective.
Education within the health care system: strengthen content on FASD diagnosis and prevention in residency training curricula in obstetrics and gynecology, pediatrics, psychiatry, and family medicine. Raising diagnostic awareness to increase early diagnosis rates can maximize the effect of preventing secondary disabilities.